U.S. Markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.8099%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3921
    -0.0091 (-0.6529%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.3012%)
     
  • BTC-USD

    45,813.41
    -2,238.51 (-4.66%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

PTC Therapeutics to Commence Phase II/III Coronavirus Study in US

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

PTC Therapeutics, Inc. PTCT announced that it has received authorization from the FDA to initiate a phase II/III study on its investigational oral DHODH inhibitor PTC299 for the potential treatment of coronavirus disease (COVID-19). The company plans to initiate an integrated study shortly in two stages in the United States.

The study will evaluate the safety and efficacy of PTC299 in the given patient population. The primary objective of the evaluation is to check the clinical efficacy of PTC299 as assessed by time to respiratory improvement in adults hospitalized with COVID-19 versus placebo.

Per the company, PTC299 has the potential to address two critical elements of COVID-19. For instance, it can reduce the high viral replication and also selectively attenuate the uncontrolled inflammatory response resulting from the SARS-CoV-2 infection.

Shares of PTC Therapeutics have increased 4.8% so far this year against the industry’s decrease of 5.4%.


Notably, PTC299 is a next-generation, oral selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH. The candidate is also being developed for the treatment of various oncological indications and is already evaluated in nine clinical studies in more than 300 individuals.

Another clinical study on PTC299 is also underway for acute myeloid leukemia (AML).

We remind investors that earlier this month, small biotech Immunic, Inc. IMUX too received allowance from the FDA to initiate a phase II study on its oral DHODH inhibitor IMU-838 for treating the deadly coronavirus disease. Top-line data from the same is expected later in 2020.

Notably, several other big companies are also working on developing new treatments/antibodies to combat the COVID-19 disease.

Pharma giant Eli Lilly LLY already has two antibody candidates in phase I studies for treating COVID-19.

Regeneron REGN is developing REGN-COV2, a novel investigational antibody "cocktail" treatment, designed to prevent and treat the SARS-CoV-2 virus. Clinical studies on the same began this month.

Zacks Rank

PTC Therapeutics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks’ Single Best Pick to Double

From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.

Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.

Click Here, See It Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
 
Eli Lilly and Company (LLY) : Free Stock Analysis Report
 
PTC Therapeutics, Inc. (PTCT) : Free Stock Analysis Report
 
Immunic, Inc. (IMUX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research